Articles

At retatrutide's weight loss of 28 percent (TRIUMPH-1, 80 weeks), calorie restriction alone loses roughly 35 percent of total weight as lean tissue, approximately 9–11 kg on a 90 kg baseline. Combining resistance training with protein at or above 1·6 g/kg/day can reduce that lean fraction to 10–15 percent, protecting an estimated 6–9 kg. No retatrutide-specific RCT confirms this arithmetic.

TRIUMPH-2's 80-week Phase 3 data show retatrutide at 12 mg produced 20.8% mean body-weight loss in adults with type 2 diabetes — 7.5 percentage points below non-diabetic TRIUMPH-1. The 2025 Coskun DXA sub-study found lean mass comprised approximately 35% of weight lost in the T2D population, driven by compounded anabolic resistance and a pre-existing sarcopenic phenotype.

Yıldırım et al. (Scientific Reports, 2026) documented that BPC-157 at 20 µg/kg IP improved skeletal muscle architecture on Masson-trichrome staining, reduced collagen deposition, and significantly lowered caspase-3 and IL-6 immunohistochemical expression versus untreated IRI controls. These structural findings extend the 2026 Demirtaş critical review's oxidative biomarker data into tissue-level morphology — exclusively in rodent models with no validated human translation.

Resistance training materially preserves lean mass during GLP-1 treatment. The Karakasis 2025 meta-analysis found GLP-1 monotherapy loses approximately 25% of total weight as lean tissue; exercise-combined arms cut that fraction to roughly 10–15%. On a 15 kg semaglutide weight-loss course, structured training can prevent 2–4 kg of lean tissue loss, a 60–70% reduction in lean mass attrition.

GLP-1–based therapies produce measurable lean-mass loss in every controlled trial: 20–39% of total weight lost is lean tissue rather than fat. The 2026 Laverde meta-analysis reframes this as a proportional lean-to-fat ratio improvement, but absolute lean-mass deficits of 3–8 kg remain documented. Whether that penalty matters depends on baseline muscle reserve and co-management of resistance training and protein intake.

The 2026 Demirtaş critical review (IJMS 27(18):8344) documents BPC-157-associated MDA reduction, TOS attenuation, and SOD/catalase restoration in rodent IRI models. Rodent lower-extremity IRI generates a 3–8× MDA elevation above sham baseline, roughly 3–5× larger than the 1–2× MDA rise seen in high-intensity human exercise. That magnitude gap is the central numeric fact performance practitioners need to hold.

For all three compounds, the evidence chain breaks at the species boundary. A 2026 UCLA scoping review of 565 studies across six unapproved peptides found that BPC-157, TB-500, and GHK-Cu have no completed human RCTs measuring body composition or athletic recovery as primary endpoints. Preclinical mechanisms are quantified; human performance outcomes are not.

The 2026 Demirtaş critical review in International Journal of Molecular Sciences (IJMS 27(18):8344) appraises the preclinical IRI evidence for BPC-157 as mechanistically coherent but structurally limited: consistent rodent results across oxidative stress, endothelial, and apoptotic endpoints, yet concentrated in a single research group, delivered exclusively via parenteral routes, and without a validated pharmacokinetic bridge to human performance contexts.

MK-677 (ibutamoren) produces a statistically significant but modest lean-mass gain of approximately 1.6 kg above placebo over 12 months in the only controlled human trial. It simultaneously raises fasting glucose, reduces insulin sensitivity, and generated a congestive heart failure signal that terminated a separate elderly-population trial. The lean-mass benefit is real but narrow, and the cardiometabolic cost is not negligible.

Retatrutide's glucagon receptor (GCGR) component creates a dual-edged lean-mass signal: it drives hepatic amino acid catabolism via urea-cycle upregulation — a direct lean-mass liability — while simultaneously increasing energy expenditure through fat oxidation, reducing substrate pressure on muscle protein. Resistance training resolves this tension by redirecting circulating amino acids toward myofibrillar synthesis rather than hepatic gluconeogenesis.

Mostly animal data, with one narrow human exception. A 2026 UCLA Health review of 565 studies across six unapproved peptides concluded that human evidence is sparse and marketing claims substantially outpace the clinical record. MK-677 has the strongest human dataset, but its one meaningful RCT enrolled elderly adults rather than athletes, and total fat mass rose alongside lean-mass gains.

The 2026 systems medicine review of semaglutide (Tandfonline, Expert Review of Clinical Pharmacology) integrates proteomic and metabolomic datasets with major RCT outcomes to show that semaglutide reconfigures substrate flux across liver, skeletal muscle, and adipose tissue simultaneously. These molecular shifts begin 4 to 8 weeks before measurable weight loss, creating a distinct periodization window for diet and training intervention.